{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:18:24Z","timestamp":1779099504242,"version":"3.51.4"},"reference-count":41,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Lipoprotein(a) (Lp(a)) is a genetically determined lipoprotein associated with atherosclerotic cardiovascular disease (ASCVD). Its prognostic role in type 2 diabetes mellitus (T2DM) remains unclear. We aimed to evaluate the association of Lp(a) with first myocardial infarction (MI), cardiovascular (CV) mortality, and all-cause mortality, with a focus on sex differences. Methods: We retrospectively analysed patients with T2DM and no prior MI who were hospitalised between 2000 and 2018 and had baseline Lp(a) measurements. Patients were followed until MI, death, or the end of 2023. Lp(a) was categorised as \u226450, 51\u201390, and &gt;90 mg\/dL. Cox proportional hazards models were adjusted for low-density lipoprotein cholesterol, arterial hypertension, and estimated glomerular filtration rate &lt; 60 mL\/min\/1.73 m2, with attained age used as the time scale. Results: A total of 2967 patients (37.5% women) were included. During follow-up, 12.5% of patients experienced MI, 36.4% died from CV causes, and 68.8% died from any cause. A significant interaction between Lp(a) and sex was observed for MI. In sex-specific analyses, Lp(a) &gt; 50 mg\/dL was associated with a higher risk of first MI in women (51\u201390 mg\/dL: HR 1.79, 95% CI 1.07\u20132.99; &gt;90 mg\/dL: HR 2.67, 95% CI 1.66\u20134.32), whereas no significant association was observed in men. Elevated Lp(a) \u2265 50 mg\/dL was also associated with higher CV mortality overall (51\u201390 mg\/dL: HR 1.42, 95% CI 1.07\u20131.89; &gt;90 mg\/dL: HR 1.38, 95% CI 1.01\u20131.91), without a significant interaction with sex. No significant associations were observed for all-cause mortality. Conclusions: In patients with T2DM, elevated Lp(a) &gt; 50 mg\/dL was associated with increased risk of first MI, predominantly in women, and with higher CV mortality overall. Lp(a) may serve as a valuable marker for CV risk stratification in this population.<\/jats:p>","DOI":"10.3390\/diagnostics16101520","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:56:27Z","timestamp":1779094587000},"page":"1520","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipoprotein(a) as a Risk Factor for Myocardial Infarction, Cardiovascular, and All-Cause Mortality in Patients with Type 2 Diabetes Mellitus"],"prefix":"10.3390","volume":"16","author":[{"given":"Jerneja","family":"\u010cuje\u0161","sequence":"first","affiliation":[{"name":"University Department of Cardiology and Angiology, University Medical Center Maribor, Ljubljanska Ulica 5, 2000 Maribor, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9239-2133","authenticated-orcid":false,"given":"Vojko","family":"Kani\u010d","sequence":"additional","affiliation":[{"name":"University Department of Cardiology and Angiology, University Medical Center Maribor, Ljubljanska Ulica 5, 2000 Maribor, Slovenia"},{"name":"Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7872-586X","authenticated-orcid":false,"given":"Petra","family":"Povalej Br\u017ean","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia"},{"name":"Faculty of Electrical Engineering and Computer Science, University of Maribor, Koro\u0161ka Cesta 46, 2000 Maribor, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"\u0160uran","sequence":"additional","affiliation":[{"name":"University Department of Cardiology and Angiology, University Medical Center Maribor, Ljubljanska Ulica 5, 2000 Maribor, Slovenia"},{"name":"Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration with the EASD: The Task Force for Diabetes, Pre-Diabetes, and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): Resurrected by Genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and Cardiovascular Disease","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clin. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A European Atherosclerosis Society Consensus Statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/aje\/kwp043","article-title":"Lipid Changes during the Menopause Transition in Relation to Age and Weight: The Study of Women\u2019s Health Across the Nation","volume":"169","author":"Derby","year":"2009","journal-title":"Am. J. Epidemiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-Genetic Influences on Lipoprotein(a) Concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk","volume":"139","author":"Fazio","year":"2019","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sosnowska, B., Surma, S., and Banach, M. (2022). Targeted Treatment against Lipoprotei(a): The Coming Breakthrough in Lipid Lowering Therapy. Pharmaceuticals, 15.","DOI":"10.3390\/ph15121573"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High Lipoprotein(a) and High Risk of Mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population: The Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.hlc.2020.09.932","article-title":"Lipoprotein(a) in Patients With Type 2 Diabetes and Premature Coronary Artery Disease in the Coronary Care Unit","volume":"30","author":"Lan","year":"2021","journal-title":"Heart Lung Circ."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12933-020-01083-8","article-title":"Lipoprotein(a) Predicts Recurrent Worse Outcomes in Type 2 Diabetes Mellitus Patients with Prior Cardiovascular Events: A Prospective, Observational Cohort Study","volume":"19","author":"Zhang","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"A8937","DOI":"10.1161\/circ.144.suppl_1.8937","article-title":"Abstract 8937: Type 2 Diabetes Significantly Modulates the Power of Lipoprotein(a) to Predict Cardiovascular Events and Mortality in Young Coronary Artery Disease Patients","volume":"144","author":"Mader","year":"2021","journal-title":"Circulation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2362.2006.01604.x","article-title":"Lipoprotein(a), Type 2 Diabetes and Vascular Risk in Coronary Patients","volume":"36","author":"Saely","year":"2006","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0735-1097(20)32663-2","article-title":"Lipoprotein(a) Related Risk for All-Cause and Cardiovascular Mortality in Us Adults According to Diabetes Status","volume":"75","author":"Fras","year":"2020","journal-title":"JACC"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11239-022-02701-w","article-title":"Lipoprotein(a) Levels and Risk of Adverse Events after Myocardial Infarction in Patients with and without Diabetes","volume":"54","author":"Silverio","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12933-021-01363-x","article-title":"Association of Sex-Specific Differences in Lipoprotein(a) Concentrations with Cardiovascular Mortality in Individuals with Type 2 Diabetes Mellitus","volume":"20","author":"Markus","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"ehad655.1243","DOI":"10.1093\/eurheartj\/ehad655.1243","article-title":"Effect of LPA Gene on CAD Risk among Diabetic Patients","volume":"44","author":"Sousa","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1194\/jlr.P049015","article-title":"Serum Lipoprotein(a) Concentrations Are Inversely Associated with T2D, Prediabetes, and Insulin Resistance in a Middle-Aged and Elderly Chinese Population","volume":"56","author":"Ding","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref_24","unstructured":"National Kidney Foundation (2002). K\/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Am. J. Kidney Dis., 39, S1\u2013S266."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and Cardiovascular Disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e016318","DOI":"10.1161\/JAHA.119.016318","article-title":"Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events","volume":"9","author":"Willeit","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the Risk of Cardiovascular Disease in the European Population: Results from the BiomarCaRE Consortium","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12933-024-02348-2","article-title":"Lipoprotein(a) as a Cardiovascular Risk Factor among Patients with and without Diabetes Mellitus: The Mass General Brigham Lp(a) Registry","volume":"23","author":"Shiyovich","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12933-023-01881-w","article-title":"Prognostic Impacts of Diabetes Status and Lipoprotein(a) Levels in Patients with ST-Segment Elevation Myocardial Infarction: A Prospective Cohort Study","volume":"22","author":"Li","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"\u0160uran, D., Zavr\u0161nik, T., Kokol, P., Kokol, M., Sinkovi\u010d, A., Naji, F., Zavr\u0161nik, J., Bla\u017eun Vo\u0161ner, H., and Kani\u010d, V. (2023). Lipoprotein(a) As a Risk Factor in a Cohort of Hospitalised Cardiovascular Patients: A Retrospective Clinical Routine Data Analysis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12093220"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"\u0160uran, D., Kani\u010d, V., Kokol, P., Zavr\u0161nik, T., Verhnjak, F., \u017dlahti\u010d, B., Sinkovi\u010d, A., and Naji, F.H. (2024). Lipoprotein(a) as a Risk Factor for Recurrent Acute Myocardial Infarction and Mortality: Insights from Routine Clinical Practice. Diagnostics, 14.","DOI":"10.20944\/preprints202410.1372.v1"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","article-title":"Sex Differences of Lipoprotein(a) Levels and Associated Risk of Morbidity and Mortality by Age: The Copenhagen General Population Study","volume":"355","author":"Simony","year":"2022","journal-title":"Atherosclerosis"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Pino, B.D., Gorini, F., Gaggini, M., Landi, P., Pingitore, A., and Vassalle, C. (2023). Lipoprotein(a), Cardiovascular Events and Sex Differences: A Single Cardiological Unit Experience. J. Clin. Med., 12.","DOI":"10.3390\/jcm12030764"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijcard.2010.02.021","article-title":"Lipoprotein(a) Is Strongly Associated with Coronary Artery Calcification in Type-2 Diabetic Women","volume":"150","author":"Qasim","year":"2011","journal-title":"Int. J. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/eurheartj\/ehz913","article-title":"Does Type 2 Diabetes Confer Higher Relative Rates of Cardiovascular Events in Women Compared with Men?","volume":"41","author":"Malmborg","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"\u0160uran, D., Bla\u017eun Vo\u0161ner, H., Zavr\u0161nik, J., Kokol, P., Sinkovi\u010d, A., Kani\u010d, V., Kokol, M., Naji, F., and Zavr\u0161nik, T. (2022). Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.923797"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"570598","DOI":"10.1155\/2012\/570598","article-title":"Vascular Disease in Diabetic Women: Why Do They Miss the Female Protection?","volume":"2012","author":"Dantas","year":"2012","journal-title":"Exp. Diabetes Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S2213-8587(17)30096-7","article-title":"Relations between Lipoprotein(a) Concentrations, LPA Genetic Variants, and the Risk of Mortality in Patients with Established Coronary Heart Disease: A Molecular and Genetic Association Study","volume":"5","author":"Zewinger","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10654-022-00956-4","article-title":"Circulating Lipoprotein(a) and All-Cause and Cause-Specific Mortality: A Systematic Review and Dose-Response Meta-Analysis","volume":"38","author":"Amiri","year":"2023","journal-title":"Eur. J. Epidemiol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., Peto, R., Barnes, E.H., and Keech, A. (2010). Efficacy and Safety of More Intensive Lowering of LDL Cholesterol: A Meta-Analysis of Data from 170,000 Participants in 26 Randomised Trials. Lancet, 376, 1670\u20131681.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Emerging Risk Factors Collaboration, Di Angelantonio, E., Sarwar, N., Perry, P., Kaptoge, S., Ray, K.K., Thompson, A., Wood, A.M., Lewington, S., and Sattar, N. (2009). Major Lipids, Apolipoproteins, and Risk of Vascular Disease. JAMA, 302, 1993\u20132000.","DOI":"10.1001\/jama.2009.1619"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/10\/1520\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T09:34:26Z","timestamp":1779096866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/10\/1520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["diagnostics16101520"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16101520","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}